Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Click here to sign up for SAGE Journal Email Alerts today!

Sign In to gain access to subscriptions and/or personal tools.
Diabetes and Vascular Disease Research
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Chapman, M J.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Chapman, M J.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

The effects of fibrates on lipid metabolism and inflammation in type 2 diabetes

M John Chapman

Dyslipidaemia & Atherosclerosis Research Unit, National Institute for Health & Medical Research (INSERM), Unite 551, Hôpital de la Pitié, Paris, France.

Type 2 diabetes is associated with a cluster of cardiovascular risk factors that together promote macrovascular and microvascular disease. An atherogenic dyslipidaemia, characterised by an increase in serum triglyceride-rich lipoproteins, a decrease in plasma levels of high-density lipoprotein cholesterol (HDL-C) and increased prevalence of small, dense low-density lipoprotein (LDL) particles (although LDL-C levels are normal or only modestly elevated), as well as chronic inflammation, play key roles in the pathogenesis of diabetes-related complications. As peroxisome proliferator-activated receptor a agonists, the fibrates exert an integrated action to favour normalisation of lipid metabolism, cholesterol homeostasis and reverse cholesterol transport, inflammation and haemostasis, suggesting potential efficacy in preventing vascular complications of diabetes. By synergistic therapeutic targeting of abnormalities in lipid metabolism and inflammation, fenofi-brate can promote anti-atherogenic effects at the arterial wall, as demonstrated in the Diabetes Atherosclerosis Intervention Study (DAIS), and reduction of total cardiovascular events, as shown in the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) trial.

Key Words: type 2 diabetes • lipid metabolism • inflammation • vascular complications

Diabetes and Vascular Disease Research, Vol. 3, No. 1 Suppl, S6-S9 (2006)
DOI: 10.1177/147916410600300103
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?